Sygnature Discovery Limited
Chris Blunt has a diverse work experience in the chemistry field. They started their career as a Graduate Research Assistant at Reach Separations in 2013. They then pursued a PhD at the University of Nottingham from 2013 to 2016. Following that, they were a Postdoctoral Research Associate at Durham University and later at UCL from 2016 to 2018. In 2018, they worked as a Process Chemist at Syngenta. They joined Sygnature Discovery in 2019 and held various roles, including Medicinal Chemist and Computational Chemist, eventually becoming a Lead Scientist.
Chris Blunt attended Bedford Modern School from 2004 to 2009, where they obtained an A level in Chemistry, Biology and Business studies. Following that, they pursued their undergraduate studies at the University of Nottingham from 2009 to 2013, earning an MSci degree in Chemistry with a year in industry. Later, they continued their education at the University of Nottingham from 2013 to 2016, completing their Doctor of Philosophy (PhD) in Organic Chemistry.
This person is not in any offices
Sygnature Discovery Limited
2 followers
Sygnature Discovery are a leading drug discovery CRO with expertise across a range of therapeutic and biological target classes. An expert partner in disciplines including Medicinal and Computational Chemistry, In Vitro and In Vivo Pharmacology, DMPK, supported by informatics.